Quick Takeaways
- Lin Bioscience International Ltd. filed SCHEDULE 13G for Belite Bio, Inc Ordinary shares, par value US$0.0001 per share (BLTE).
- Disclosed ownership: 54%.
- Date of event: 31 Dec 2024.
Lin Bioscience International Ltd. - 31 Dec 2024 SCHEDULE 13G Report for Belite Bio, Inc Ordinary shares, par value US$0.0001 per share (BLTE)
- Filing Manager
- Lin Bioscience International Ltd.
- Reporting Manager
- Lin Bioscience International Ltd.
- Symbol
- BLTE
- Shares outstanding
- 31,834,754 shares
- Disclosed Ownership
- 17,095,263 shares
- Ownership
- 54%
- Form type
- SCHEDULE 13G
- Filing time
- 21 Jan 2025, 06:01:07 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"Lin Bioscience International Ltd. disclosed 54% ownership in Belite Bio, Inc Ordinary shares, par value US$0.0001 per share (BLTE) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 21 Jan 2025, 06:01.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Lin Bioscience International Ltd. | 54% | 17,095,263 | 17,095,263 | 0 | Yu-Hsin Lin | Yu-Hsin Lin/Director |